Details of the Drug Reposition

General Information of This Drug (ID: DMMJTYP)

• Drug Name: Frexalimab (DMMJTYP)
• Drug Type: Antibody

Information on Drug Reposition of This Drug

3 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Systemic lupus erythematosus	DISI1SZ7	4A40.0	Phase 2	[1]
Sjogren syndrome	DISUBX7H	4A43.20	Phase 2	[2]
Multiple sclerosis	DISB2WZI	8A40	Phase 2	[3]

References

• [1] ClinicalTrials.gov (NCT05039840) Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04572841) A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Adult Patients With Primary Sj?gren's Syndrome (pSjS). U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT04879628) A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis. U.S.National Institutes of Health.